Graft-versus-host disease (GVHD) is a common complication of allogeneic hematopoietic stem cell transplantation (HSCT) that occurs when the donated (graft) cells are rejected and attack the host’s cells as foreign. GVHD can progress from mild to severe forms as either acute GVHD (aGVHD) or chronic GVHD (cGVHD). Both aGVHD and cGVHD commonly affect organs such as the skin, gastrointestinal (GI) tract, liver, oral mucosa, and eyes (Hymes et al., 2012). The global distribution of GVHD is directly dependent on transplantation-related factors, including the donor type, the age of the donor and the recipient, the sex parity between the recipient and the donor, the pre-transplantation conditioning regimen, and the use of GVHD prophylaxis pre- and/or post-transplantation. Around 30–70% of HSCT recipients will develop aGVHD, and another 30–70% will develop cGVHD independent of aGVHD (Arora et al., 2011; Champlin et al., 2000; Hymes et al., 2012; Jagasia et al., 2012; Joseph et al., 2008; Przepiorka et al., 1999). GVHD can be unpleasant and reduces the quality of life following HSCT, and in severe forms, significantly increases the risk of non-relapse mortality (Hymes et al., 2012; Wood et al., 2013). The number of persons with GVHD will continue to increase with the increase in survival of patients with GVHD and the increase in the number of patients who are at risk of developing aGVHD and cGVHD due to the increase in the number of allogeneic HSCTs performed worldwide (Joseph et al., 2008; Lee et al., 2003; Wood et al., 2013).
This report provides an overview of the risk factors, comorbidities, and the global and historical trends for the diagnosed incidence of HSCTs (including first, multiple, and re-transplants), segmented by transplant type (autologous and allogeneic), and the diagnosed incidence of GVHD in diagnosed incident cases of first HSCTs in the six major markets (6MM) (US, France, Germany, Italy, Spain, and UK). Publisher epidemiologists also provide a forecast for the four-year diagnosed prevalent cases of aGVHD and the five-year diagnosed prevalent cases of cGVHD in the 6MM. To forecast the diagnosed incident cases of HSCTs and the diagnosed incident and diagnosed prevalent cases of GVHD in the 6MM, Publisher epidemiologists selected nationally-representative, population-based studies that provided the diagnosed incidence and the overall survival (OS) rates for HSCTs and GVHD in the 6MM
Publisher epidemiologists forecast an increase in the diagnosed incident cases of aGVHD in the 6MM, from 8,062 diagnosed incident cases in 2013 to 11,568 diagnosed incident cases in 2023, at an Annual Growth Rate (AGR) of 4.35%, during the forecast period. In 2023, the US will have the highest number of diagnosed incident cases of aGVHD in the 6MM, with 4,989 diagnosed incident cases, whereas Spain will have the lowest number of diagnosed incident cases of aGVHD, with 704 diagnosed incident cases.
Similarly, Publisher epidemiologists forecast an increase in the diagnosed incident cases of cGVHD in the 6MM, from 7,359 diagnosed incident cases in 2013 to 10,485 diagnosed incident cases in 2023, at an AGR of 4.25% during the forecast period. In 2023, the US will have the highest number of diagnosed incident cases of cGVHD in the 6MM, with 4,425 diagnosed incident cases, whereas Spain will have the lowest number of diagnosed incident cases of cGVHD, with 648 diagnosed incident cases. Publisher epidemiologists held the diagnosed incidence of aGVHD and cGVHD constant throughout the forecast period; therefore, changes in the diagnosed incidence of allogeneic HSCTs in the respective markets, in combination with population changes, are driving the increase in the diagnosed incident cases of aGVHD and cGVHD.
Know more about this report at : http://mrr.cm/ZWQ
About Market Research Reports, Inc.
Market Research Reports, Inc. is the world's leading source for market research reports and market data. We provide you with the latest market research reports on global markets, key industries, leading companies, new products and latest industry analysis & trends.
Mr. Amitava Sen
Vice President - Sales & Marketing
Market Research Reports, Inc.
Tel USA: +1-302-703-7787
Tel India: +91-80-26860858